Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jinyouping (rotigotine)
- Development stage
- Unknown
- Lead developer
- Luye Pharma
- Modality
- Small Molecules
- Administration
- Intramuscular
01
Overview
Jinyouping (LY03003) is an extended-release microsphere formulation of rotigotine, a non-ergoline dopamine receptor agonist, developed by Luye Pharma Group. Utilizing a novel drug delivery system (NDDS), the drug is designed to provide continuous and stable release of rotigotine over a seven-day period following a single intramuscular injection. This weekly dosing regimen aims to overcome the limitations of daily transdermal patches or oral medications, such as skin irritation or fluctuating plasma concentrations, thereby improving patient compliance and providing more consistent stimulation of dopamine receptors. Rotigotine acts as a potent agonist at D1, D2, and D3 receptors, which are critical in the management of motor symptoms in Parkinson's disease. Jinyouping was approved by the China National Medical Products Administration (NMPA) in May 2024, making it the first long-acting microsphere formulation of rotigotine approved globally.
- Brand names
- Jinyouping
- Other names
- Rotigotine Microspheres for InjectionRotigotine Extended-Release Microspheres for Injection
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))ADRA2B (α2B)DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)DRD4 (Dopamine D4 Receptor)DRD5 (Dopamine D5 Receptor)
Beyond the preview
Go deeper on Jinyouping (rotigotine).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jinyouping (rotigotine).